Yong Yin

Prof. Dr. Yong Yin

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2023 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
TCTingting Chen
Tingting Chen
JLJiafu Leng
Jiafu Leng
JTJun Tan
Jun Tan
YZYongjun Zhao
Yongjun Zhao
SXShanshan Xie
Shanshan Xie
YYYong Yin
Yong Yin

22 December 2023 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
YGYa-Li Guo
Ya-Li Guo
JYJing-Wen Yu
Jing-Wen Yu
YCYan Cao
Yan Cao
KCKe-Xin Cheng
Ke-Xin Cheng
SDSuo-Nan-Mu Dong-Zhi
Suo-Nan-Mu Dong-Zhi
CLCao-Long Li
Cao-Long Li

6 December 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JLJiafu Leng
Jiafu Leng
YZYongjun Zhao
Yongjun Zhao
PSPing Sheng
Ping Sheng
YXYuanzheng Xia
Yuanzheng Xia
TCTingting Chen
Tingting Chen
LKLing-Yi Kong
Ling-Yi Kong

5 February 2015 in RSC Advances
Verified
Journal Article
Closed access
PDF file
FQFang Qiao
Fang Qiao
YYYong Yin
Yong Yin
YSYu-Ning Shen
Yu-Ning Shen
SWShe-Feng Wang
She-Feng Wang
SSShao Sha
Shao Sha
HZHailiang Zhu
Hailiang Zhu
A series of 4-alkoxyquinazoline derivatives containing the 1,3,4-oxadiazole scaffold have been designed and synthesized, and their inhibitory activities were also tested against A549, MCF-7 and Hela. Of these compounds, 2-(3,4-dimethoxybenzyl)-5-((quinazolin-4-yloxy)methyl)-1,3,4-oxadiazole (compound 4j) showed the most potent inhibitory activity (IC50 = 0.23 μM for MCF-7, IC50 = 0.38 μM for A549 and IC50 = 0.32 μM for Hela) and the effect was better than the positive control drug Tivozanib (IC50 = 0.38 μM for MCF-7, IC50 = 0.62 μM for A549 and IC50 = 0.34 μM for Hela). A docking simulation was performed to position compound 4j into the VEGFR active site to determine the probable binding model. These results suggested that compound 4j with potent inhibitory activity in tumor growth inhibition may be a potential anticancer agent.

16 April 2022 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
XYXiang-Yu Yan
Xiang-Yu Yan
JLJia-Fu Leng
Jia-Fu Leng
TCTing-Ting Chen
Ting-Ting Chen
YZYong-Jun Zhao
Yong-Jun Zhao
LKLing-Yi Kong
Ling-Yi Kong
YYYong Yin
Yong Yin

3 March 2024 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SXShanshan Xie
Shanshan Xie
JLJiafu Leng
Jiafu Leng
SZShifang Zhao
Shifang Zhao
LZLiqiao Zhu
Liqiao Zhu
MZMengyu Zhang
Mengyu Zhang
YYYong Yin
Yong Yin